HK1215441A1 - 人血清白蛋白结合化合物及其融合蛋白 - Google Patents

人血清白蛋白结合化合物及其融合蛋白 Download PDF

Info

Publication number
HK1215441A1
HK1215441A1 HK16103286.9A HK16103286A HK1215441A1 HK 1215441 A1 HK1215441 A1 HK 1215441A1 HK 16103286 A HK16103286 A HK 16103286A HK 1215441 A1 HK1215441 A1 HK 1215441A1
Authority
HK
Hong Kong
Prior art keywords
serum albumin
human serum
fusion proteins
albumin binding
binding compounds
Prior art date
Application number
HK16103286.9A
Other languages
English (en)
Chinese (zh)
Inventor
Fabian Buller
Ulrich WÜLLNER
Irene Zbinden
Isabella Attinger-Toller
Ulrike Von Der Bey
Susann König-Friedrich
Julian Bertschinger
Dragan Grabulovski
Patricia Henne
Original Assignee
Covagen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen Ag filed Critical Covagen Ag
Publication of HK1215441A1 publication Critical patent/HK1215441A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16103286.9A 2013-01-03 2013-12-18 人血清白蛋白结合化合物及其融合蛋白 HK1215441A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13150171.0 2013-01-03
EP13150171.0A EP2752426A1 (en) 2013-01-03 2013-01-03 Human serum albumin binding compounds and fusion proteins thereof
PCT/EP2013/077227 WO2014106583A1 (en) 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof

Publications (1)

Publication Number Publication Date
HK1215441A1 true HK1215441A1 (zh) 2016-08-26

Family

ID=47458817

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103286.9A HK1215441A1 (zh) 2013-01-03 2013-12-18 人血清白蛋白结合化合物及其融合蛋白

Country Status (7)

Country Link
US (2) US9790475B2 (enExample)
EP (2) EP2752426A1 (enExample)
JP (1) JP2016508143A (enExample)
AU (1) AU2013372004B2 (enExample)
CA (1) CA2896962A1 (enExample)
HK (1) HK1215441A1 (enExample)
WO (1) WO2014106583A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018220516B2 (en) 2017-02-16 2025-03-06 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
CN107353346A (zh) * 2017-08-09 2017-11-17 芜湖英特菲尔生物制品产业研究院有限公司 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
CA3170750A1 (en) * 2020-03-06 2021-09-10 Yi Shi Serum albumin binding nanobody compositions and methods for using the same
CN116284373A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
MX354717B (es) * 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.

Also Published As

Publication number Publication date
AU2013372004A1 (en) 2015-07-16
JP2016508143A (ja) 2016-03-17
US20190169581A1 (en) 2019-06-06
EP2941439B1 (en) 2018-01-31
CA2896962A1 (en) 2014-07-10
US20160076011A1 (en) 2016-03-17
WO2014106583A1 (en) 2014-07-10
EP2941439A1 (en) 2015-11-11
EP2752426A1 (en) 2014-07-09
US9790475B2 (en) 2017-10-17
US10364419B2 (en) 2019-07-30
AU2013372004B2 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
HK1215441A1 (zh) 人血清白蛋白结合化合物及其融合蛋白
EP4442816A3 (en) Mutated glycoprotein of vesicular stomatitis virus
NZ628625A (en) Polypeptides binding to human complement c5
MX389173B (es) Receptores de celulas t.
AU2017248122A1 (en) T cell receptors
EP4389898A3 (en) T cell receptors
HK1214605A1 (zh) 具有抗肿瘤活性的新颖的双特异性结合分子
MX2015003310A (es) Moleculas de union il-17a novedosas y usos medicos de las mismas.
EA201892250A1 (ru) Вакцина против rsv
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2014202616A3 (en) Rasamsonia gene and use thereof
RU2018132044A (ru) Антитела против тау
WO2018004308A3 (ko) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
IL288541B (en) Vaccine against rsv
EP4374913A3 (en) Novel human serum albumin mutant
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
WO2015140638A8 (en) Glycosylated vegf decoy receptor fusion protein
EA201491277A1 (ru) Противораковый слитый белок
WO2016130628A8 (en) Griffithsin mutants
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
WO2014202622A3 (en) Rasamsonia gene and use thereof
HK1244460A1 (zh) 丝氨酸融合多肽和其使用方法
MY176200A (en) Binding polypeptides having a mutated scaffold
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins